---
title: Development and preclinical characterization of a novel radiotheranostic EphA2-targeting
  bicyclic peptide
date: '2024-09-06'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39239524/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240906182443&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Erythropoietin-producing hepatocellular receptor A2 (EphA2), is a receptor
  tyrosine kinase involved in cell-cell interactions. It is known to be overexpressed
  in various tumors and is associated with poor prognosis. EphA2 has been proposed
  as a target for theranostic applications. Low molecular weight peptide-based scaffolds
  with low nanomolar affinities have been shown to be ideal in such applications.
  Bicyclic peptides have emerged as an alternative to traditional peptides for this
  ...
disable_comments: true
---
Erythropoietin-producing hepatocellular receptor A2 (EphA2), is a receptor tyrosine kinase involved in cell-cell interactions. It is known to be overexpressed in various tumors and is associated with poor prognosis. EphA2 has been proposed as a target for theranostic applications. Low molecular weight peptide-based scaffolds with low nanomolar affinities have been shown to be ideal in such applications. Bicyclic peptides have emerged as an alternative to traditional peptides for this ...